시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 가족성 아밀로이드성 다발성 신경병증 시장 보고서(2025년)
Familial Amyloid Polyneuropathy Global Market Report 2025
상품코드 : 1764312
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,292,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,095,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,897,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

가족성 아밀로이드성 다발성 신경병증 시장 규모는 향후 몇 년간 강력한 성장이 전망될 예정입니다. 기간 중 예상되는 성장 요인으로는 희귀질환 치료에 특화된 정부의 대처나 자금 제공의 확대, 혁신적인 치료법을 검사하는 임상 검사 증가, 치료법 개선에 대한 수요를 부추기는 환자 옹호·지원 단체 증가, 신흥 시장에 있어서의 헬스 케어 인프라에의 액세스 강화, 고도 진단 기술의 이용 가능성의 확대 등을 들 수 있습니다. 이 기간에 예상되는 주요 동향에는 유전자 시퀀싱 기술의 진보, 맞춤형 의료의 채용, 바이오 마커 동정 기술의 진보, 약물전달 시스템의 개선, 디지털 헬스 툴과 원격 의료 등이 있습니다.

유전자 치료에 대한 관심 증가는 향후 가족성 아밀로이드성 다발성 신경병증 시장의 성장을 견인할 것으로 예측됩니다. 따라서 단순히 증상을 완화할 뿐만 아니라 영구적 또는 영구적인 치료법을 제공할 수 있으며 지원을 모으고 있습니다. 예를 들어, 2023년 7월 미국을 거점으로 하는 전문 조직인 미국 유전자·세포 치료 학회(ASGCT)와 미국을 거점으로 하는 의약품·기기 제공업체 Citeline은 2상 임상 검사 중 유전자 치료 수가 2023년 1분기 말 247건에서 2분기 말 260건으로 5% 증가했다고 보고했습니다.

가족성 아밀로이드성 다발성 신경병증 시장의 주요 기업은 RNA 간섭(RNAi) 치료 등 질병 진행을 늦추고 환자의 예후를 개선하기 위한 시장 개척에 주력하고 있습니다. 이를 통해 유전자를 침묵시키고, 유해한 단백질의 생산을 차단하고, 유전성 질환의 근원으로부터 대처합니다. 예를 들어, 2025년 3월 미국 소재 바이오 제약 회사인 알닐람 파마슈티컬스는 성인에서 야생형 또는 유전성 트랜스티레틴 매개 아밀로이드증(ATTR-CM)으로 인한 심근증 치료제로 FDA 승인을 받은 암부트라(부트리시란)를 출시했습니다. HELIOS-B 3상 임상 검사에서 입증된 바와 같이 이 질환의 근본 원인인 트란스티레틴(TTR) 단백질의 생산을 감소시킴으로써 심혈관계 사망률, 입원, 심부전의 긴급 진찰을 유의하게 감소시키고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

KTH
영문 목차

영문목차

Familial amyloid polyneuropathy (FAP) is a rare inherited disorder caused by mutations in the transthyretin (TTR) gene, leading to the buildup of amyloid proteins in peripheral nerves and vital organs. This progressive condition primarily affects the nervous system, causing sensory, motor, and autonomic impairments. Early diagnosis and proper management focus on slowing disease progression, easing symptoms, and improving the patient's quality of life.

The main treatment options for familial amyloid polyneuropathy include medication, gene therapy, supportive care, pain management, and symptomatic relief. Medications help by slowing the disease's advancement, reducing symptoms, and enhancing patients' quality of life. Diagnosis can be performed using various techniques such as genetic testing, biopsy, imaging, and others, across different age groups including pediatric, adult, and geriatric patients. Treatments are distributed through multiple channels like hospital pharmacies, retail and online pharmacies, specialty pharmacies, and direct sales, and are utilized by various end-users including hospitals, specialty clinics, research institutes, and more.

The familial amyloid polyneuropathy market research report is one of a series of new reports from The Business Research Company that provides familial amyloid polyneuropathy market statistics, including the familial amyloid polyneuropathy industry global market size, regional shares, competitors with the familial amyloid polyneuropathy market share, detailed familial amyloid polyneuropathy market segments, market trends, opportunities, and any further data you may need to thrive in the familial amyloid polyneuropathy industry. This familial amyloid polyneuropathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The familial amyloid polyneuropathy market size has grown strongly in recent years. It will grow from $1.52 billion in 2024 to $1.65 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth during the historic period can be attributed to the rising prevalence of familial amyloid polyneuropathy, improved awareness and diagnosis rates driven by advances in genetic testing, increased adoption of new therapeutic and targeted treatment options, greater investment in research and development for amyloidosis therapies, and a growing elderly population vulnerable to amyloid-related neuropathies.

The familial amyloid polyneuropathy market size is expected to see strong growth in the next few years. It will grow to $2.25 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth expected during the forecast period can be attributed to expanding government initiatives and funding dedicated to rare disease treatments, a rising number of clinical trials testing innovative therapies, increased patient advocacy and support groups fueling demand for improved treatments, enhanced access to healthcare infrastructure in emerging markets, and greater availability of advanced diagnostic technologies. Key trends anticipated in this period include progress in genetic sequencing technologies, the adoption of personalized medicine, advancements in biomarker identification techniques, improvements in drug delivery systems, and the incorporation of digital health tools and telemedicine.

The increasing emphasis on gene therapy is expected to drive the growth of the familial amyloid polyneuropathy market going forward. Gene therapy involves modifying or replacing faulty genes to treat the root cause of diseases. This approach is gaining traction because it targets and repairs defective genes, potentially providing lasting or permanent cures rather than just alleviating symptoms. For familial amyloid polyneuropathy, gene therapy aims to correct or silence the mutated transthyretin (TTR) gene to prevent the buildup of harmful amyloid proteins. This reduces amyloid deposits, slows disease progression, and helps preserve nerve function. For example, in July 2023, the American Society of Gene & Cell Therapy (ASGCT), a U.S.-based professional organization, and Citeline, a U.S.-based drug and device provider, reported that the number of gene therapies in Phase II clinical trials increased from 247 at the end of the first quarter of 2023 to 260 by the end of the second quarter, a 5% rise. Thus, the growing focus on gene therapy is fueling the expansion of the familial amyloid polyneuropathy market.

Leading companies in the familial amyloid polyneuropathy market are concentrating on developing advanced therapies such as RNA interference (RNAi) treatments to slow disease progression and enhance patient outcomes. RNAi therapeutics work by silencing disease-causing genes through targeting their messenger RNA (mRNA), thereby preventing the production of harmful proteins and addressing genetic disorders at their source. For example, in March 2025, Alnylam Pharmaceuticals, a U.S.-based biopharmaceutical firm, launched AMVUTTRA (vutrisiran), which received FDA approval for the treatment of cardiomyopathy caused by wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. The therapy is administered as four subcutaneous doses annually and is designed to treat both ATTR-CM and hereditary transthyretin-mediated amyloidosis polyneuropathy (hATTR-PN). By reducing transthyretin (TTR) protein production-the underlying cause of the disease-it significantly decreases cardiovascular mortality, hospitalizations, and urgent heart failure visits, as evidenced in the HELIOS-B Phase 3 clinical trial.

In March 2023, Alnylam Pharmaceuticals, a U.S.-based developer of RNAi therapies for hereditary transthyretin-mediated amyloidosis, formed a partnership with Medison Pharma to expand global access to innovative RNAi treatments. The collaboration seeks to speed up and widen patient availability of Alnylam's RNAi therapeutics for rare and serious diseases by utilizing Medison Pharma's integrated commercialization platform across multiple international markets. Medison Pharma is a pharmaceutical company headquartered in Israel.

Major players in the familial amyloid polyneuropathy market are Pfizer Inc., AstraZeneca plc, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., NYU Langone Hospitals, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Mount Sinai Medical Center, PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Mayo Foundation for Medical Education and Research, Arcturus Therapeutics Inc., Prothena Corporation plc, Precision BioSciences Inc., Intellia Therapeutics Inc., Creative Biolabs, Stanford Health Care, Attralus Inc., Duke University Health System, and YolTech Therapeutics.

North America was the largest region in the familial amyloid polyneuropathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in familial amyloid polyneuropathy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the familial amyloid polyneuropathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The familial amyloid polyneuropathy market consists of revenues earned by entities providing services such as disease monitoring, patient support and education, neurological assessment, and genetic counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The familial amyloid polyneuropathy market also includes sales of transthyretin stabilizers, diagnostic kits, and monitoring equipment. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Familial Amyloid Polyneuropathy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on familial amyloid polyneuropathy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for familial amyloid polyneuropathy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The familial amyloid polyneuropathy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Familial Amyloid Polyneuropathy Market Characteristics

3. Familial Amyloid Polyneuropathy Market Trends And Strategies

4. Familial Amyloid Polyneuropathy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Familial Amyloid Polyneuropathy Growth Analysis And Strategic Analysis Framework

6. Familial Amyloid Polyneuropathy Market Segmentation

7. Familial Amyloid Polyneuropathy Market Regional And Country Analysis

8. Asia-Pacific Familial Amyloid Polyneuropathy Market

9. China Familial Amyloid Polyneuropathy Market

10. India Familial Amyloid Polyneuropathy Market

11. Japan Familial Amyloid Polyneuropathy Market

12. Australia Familial Amyloid Polyneuropathy Market

13. Indonesia Familial Amyloid Polyneuropathy Market

14. South Korea Familial Amyloid Polyneuropathy Market

15. Western Europe Familial Amyloid Polyneuropathy Market

16. UK Familial Amyloid Polyneuropathy Market

17. Germany Familial Amyloid Polyneuropathy Market

18. France Familial Amyloid Polyneuropathy Market

19. Italy Familial Amyloid Polyneuropathy Market

20. Spain Familial Amyloid Polyneuropathy Market

21. Eastern Europe Familial Amyloid Polyneuropathy Market

22. Russia Familial Amyloid Polyneuropathy Market

23. North America Familial Amyloid Polyneuropathy Market

24. USA Familial Amyloid Polyneuropathy Market

25. Canada Familial Amyloid Polyneuropathy Market

26. South America Familial Amyloid Polyneuropathy Market

27. Brazil Familial Amyloid Polyneuropathy Market

28. Middle East Familial Amyloid Polyneuropathy Market

29. Africa Familial Amyloid Polyneuropathy Market

30. Familial Amyloid Polyneuropathy Market Competitive Landscape And Company Profiles

31. Familial Amyloid Polyneuropathy Market Other Major And Innovative Companies

32. Global Familial Amyloid Polyneuropathy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Familial Amyloid Polyneuropathy Market

34. Recent Developments In The Familial Amyloid Polyneuropathy Market

35. Familial Amyloid Polyneuropathy Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기